Dedicated to the discovery and development of innovative therapeutics for Neurological Disorders by targeting a novel signaling pathway. 
Novel Mechanism of Action
Rejuvenating the Brain by Reversing Synaptic Loss

Identification of novel signaling pathway for regulating synaptic function and plasticity

After 20 years of studying regulation of synaptic density and function, we were the first to identify intracellular magnesium as a critical second messenger controlling synaptic 

function and plasticity. 

Discovery of compound to promote synaptogenesis and enhance synaptic function

Through molecular screening, we identified a novel compound that can selectively elevate intracellular magnesium at the synaptic terminal. In vivo, this compound increases synaptic density, function, and plasticity, and improves learning and memory.

Clinical Stage Development 
Neurodegenerative Disease and Psychiatric Disorder - Focused Pipeline

Indication

Phase II a

Phase II b

Phase III

Alzheimer's Disease:  

Anxiety/Sleep

Depression

Active

Complete

Complete

Complete

Concussion

Schizophrenia

Complete

Active

Planned

Planned

Planned

Planned

Neurocentria, Inc.

1855 Olympic Blvd., Ste. 225 Walnut Creek, CA., U.S.A.  94596

info@neurocentria.com

925-954-4868

2018 Neurocentria, Inc.